
What happened
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) priced an underwritten public offering expected to bring in about $15 million.
The company is selling 8,296,429 shares of common stock at $1.75 each and 275,000 pre-funded warrants.
The company also granted the underwriter a 30-day option to buy up to 1,285,714 more shares at the public offering price, less underwriting discounts and commissions.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Common shares offered | 8,296,429 shares | SEC 8-K Exhibit 99.2 | |
| Public offering price per share | $1.75 | SEC 8-K Exhibit 99.2 | |
| Pre-funded warrants offered | 275,000 warrants | SEC 8-K Exhibit 99.2 | |
| Underwriter option | 1,285,714 shares | SEC 8-K Exhibit 99.2 | |
| Expected gross proceeds | $15 million | SEC 8-K Exhibit 99.2 |
Read more: Insight Molecular Diagnostics (IMDX) company research
Why it matters
For holders, the financing adds cash for working capital and general corporate purposes, including research and development in the transplantation category.
The filing says the company intends to use the net proceeds for those purposes, so the raise is tied to the current operating plan.
This is a primary raise, so the company gets the cash rather than existing holders.
The pre-funded warrant piece gives certain investors another way into the deal without changing that basic result.
OptimistFi has argued that IMDX depends on payer coverage and recurring diagnostics revenue before balance-sheet pressure forces value-destructive financing, and this raise weakens that balance-sheet test.
Gross proceeds are before underwriting discounts and commissions and other offering expenses, so the headline figure is only the starting point for the cash the company keeps.
OptimistFi calculates the 30-day option equals 15.5% of the common shares in the base sale, so dilution could rise if the underwriter uses it.
Because the option can add shares later, the final equity count may end up above the initial pricing amount.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
The offering is expected to close on or about Nov. 18, 2026, subject to customary closing conditions.
A completed close would confirm the company can raise capital on the terms it priced, while a slip would weaken that read.
If the underwriter uses the option, the final share count rises beyond the base sale.
More from OptimistFi
- IMDX stock: research and coverage of Insight Molecular Diagnostics
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
Sources
- SEC 8-K Exhibit 99.2 — Pricing of the underwritten public offering announced Nov. 17, 2026.
- SEC filing
Explore OptimistFi research on Insight Molecular Diagnostics Inc.: https://optimistfi.com/stocks/IMDX
Browse Insight Molecular Diagnostics Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Insight Molecular Diagnostics Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
